Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1.25 1.15 1.35 1.25 1.25 1.25 50,192 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.3 -0.2 -0.0 - 7

Deltex Medical Group PLC Director Dealing

22/09/2020 4:03pm

UK Regulatory (RNS & others)


TIDMDEMG

RNS Number : 7723Z

Deltex Medical Group PLC

22 September 2020

 
                                                  22 September 2020 
 
                                               Deltex Medical Group plc 
                                          ("Deltex Medical" or the "Company") 
                                                   Director Dealing 
 
               Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring 
               ("ODM"), announces that David Moorhouse, Finance Director of the Company, today purchased 
           370,000 ordinary shares in the Company ("Ordinary Shares") at a price of 1.35 pence per Ordinary 
                                Share and now holds a total of 829,834 Ordinary Shares. 
 
                                       For further information, please contact:- 
                               Deltex Medical Group plc                   01243 774 837 
                       Andy Mears, CEO                            investorinfo@deltexmedical.com 
                                        David Moorhouse, Group Finance Director 
 
                                               Nominated Adviser & Broker 
                               Arden Partners plc                         020 7614 5900 
                                                     Ciaran Walsh 
                                                    Dan Gee-Summons 
 
 
                                                     Joint Broker 
                               Turner Pope Investments (TPI) Ltd          0203 657 0050 
                            Andy Thacker                               info@turnerpope.com 
                                                     Zoe Alexander 
 
 
                                                   Notes for Editors 
           Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily 
            used in critical care and general surgical procedures. Deltex Medical's proprietary oesophageal 
         Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation 
             in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates 
           a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures 
             such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic 
              space to have built a robust and credible evidence base demonstrating both the clinical and 
              economic benefits of its core technology: TrueVue Doppler. This technology has been proven 
             in a wide range of clinical trials to reduce complications suffered by patients after surgery 
                                      and consequently can save hospitals money. 
             Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians 
           with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely 
              non-invasive monitoring technology which transmits low magnitude, high frequency electrical 
            signals through the thorax and measures the changes to this signal when the heart pumps blood. 
          TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information 
         on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically 
                                                   stable patients. 
                                                      Group goal 
              Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia 
          protocols for surgical patients, as well as treating ventilated intensive care patients, including 
               ventilated COVID-19 patients. Consequently, the Group's focus is on maximising value from 
           the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical 
              practice around the world. The Group aims to provide clinicians with a single platform - a 
          'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated 
            to be deployed according to the patient's clinical condition as well as the skill and expertise 
             of the user. Doing this will enable the Group to partner with healthcare providers to support 
                               modern haemodynamic management across the whole hospital. 
         The Group is currently in the implementation phase of achieving this goal in a number of territories 
              worldwide, operating directly in the UK and the USA, and via agreements with approximately 
                                               40 distributors overseas. 
            Note: This announcement contains inside information for the purposes of Article 7 of Regulation 
                                                   (EU) No 596/2014. 
         Notification and public disclosure of transactions by persons discharging managerial responsibilities 
 ("PDMRs") and persons closely associated with them.1   Details of the persons discharging managerial responsibilities 
                                                / person closely associated 
                           a)  Names                      David Moorhouse - Finance Director 
                                            2   Reason for the notification 
                      a)  Position/status            See 1(a) above for position - classified as 
                                                               a PDMR of Deltex Medical 
                                        b)  Initial notification       Initial 
                                                         /Amendment 
                           3   Details of the issuer, emission allowance market participant, 
                                      auction platform, auctioneer or auction monitor 
                                a)  Name                       Deltex Medical Group plc 
                                  b)  LEI                        213800XN34P6LI8J6M39 
                             4   Details of the transaction(s): section to be repeated for 
                                (i) each type of instrument; (ii) each type of transaction; 
                                (iii) each date; and (iv) each place where transactions have 
                                                       been conducted 
                                                a)  Description of the 
                                                   financial instrument, 
                           type of instrument         Ordinary shares of 1 penny each ("Ordinary 
                                                                       Shares") 
                                      b)  Identification code        GB0059337583 
                                             c)  Nature of the transaction 
                                                              Purchase of Ordinary Shares 
                                 d)  Price(s) and volume(s)     Prices(s)    Volume(s) 
                                                                 1.35 pence   370,000 
                                              d)  Aggregated information 
                                                    - Aggregated volume 
                                               - Price                    N/a 
 
                                                                          N/a 
                                   e)  Date of the transaction    22 September 2020 
                        f)  Place of the transaction   London Stock Exchange, AIM Market (XLON) 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFIEAIIFFII

(END) Dow Jones Newswires

September 22, 2020 11:03 ET (15:03 GMT)

1 Year Deltex Medical Chart

1 Year Deltex Medical Chart

1 Month Deltex Medical Chart

1 Month Deltex Medical Chart
ADVFN Advertorial
Your Recent History
LSE
DEMG
Deltex Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201029 21:14:42